Patents by Inventor Steve Bottega

Steve Bottega has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ERBB3 ANTIBODIES
    Publication number: 20230365710
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/IER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Application
    Filed: April 26, 2023
    Publication date: November 16, 2023
    Inventors: Sylvie VINCENT, William M. Winston, JR., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Anti-ErbB3 antibodies
    Patent number: 11680108
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: June 20, 2023
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • ANTI-ERBB3 ANTIBODIES
    Publication number: 20200299406
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Application
    Filed: October 29, 2019
    Publication date: September 24, 2020
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Anti-ERBB3 antibodies
    Patent number: 10494441
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: December 3, 2019
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • PREDICTING TUMOR RESPONSE TO ANTI-ERBB3 ANTIBODIES
    Publication number: 20180195120
    Abstract: A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.
    Type: Application
    Filed: November 27, 2017
    Publication date: July 12, 2018
    Inventors: Sylvie Vincent, Kristan Meetze, Bin Feng, Steven Tyler, Steve Bottega, Richard Nicoletti, Donna McIntosh, Jeno Gyuris
  • ANTI-ERBB3 ANTIBODIES
    Publication number: 20180030149
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Application
    Filed: March 2, 2017
    Publication date: February 1, 2018
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Predicting tumor response to anti-ERBB3 antibodies
    Patent number: 9828635
    Abstract: A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: November 28, 2017
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, Kristan Meetze, Bin Feng, Steven Tyler, Steve Bottega, Richard Nicoletti, Donna McIntosh, Jeno Gyuris
  • Anti-ErbB3 antibodies
    Patent number: 9598498
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: March 21, 2017
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • ANTI-ERBB3 ANTIBODIES
    Publication number: 20160264679
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Application
    Filed: January 4, 2016
    Publication date: September 15, 2016
    Inventors: Sylvie Vincent, William M. Winston, JR., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Anti-ErbB3 antibodies
    Patent number: 9228021
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: January 5, 2016
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Anti-ron antibodies
    Patent number: 8829164
    Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: September 9, 2014
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
  • PREDICTING TUMOR RESPONSE TO ANTI-ERBB3 ANTIBODIES
    Publication number: 20140242597
    Abstract: A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.
    Type: Application
    Filed: October 5, 2012
    Publication date: August 28, 2014
    Applicant: AVEO PHARMACEUTICALS, INC.
    Inventors: Sylvie Vincent, Kristan Meetze, Bin Feng, Steven Tyler, Steve Bottega, Richard Nicoletti, Donna McIntosh, Jeno Gyuris
  • ANTI-RON ANTIBODIES
    Publication number: 20140066603
    Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
    Type: Application
    Filed: November 1, 2013
    Publication date: March 6, 2014
    Applicant: AVEO PHARMACEUTICALS, INC.
    Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
  • ANTI-ERBB3 ANTIBODIES
    Publication number: 20130330772
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 12, 2013
    Inventors: Sylvie Vincent, William M. Winston, JR., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Anti-RON antibodies
    Patent number: 8603478
    Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: December 10, 2013
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
  • Anti-ErbB3 antibodies
    Patent number: 8481687
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: July 9, 2013
    Assignee: Aveo Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris